Add Company
Join Now

VenatoRx Pharmaceuticals Revenue and Competitors

License our Company Data API

Location

$107M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • VenatoRx Pharmaceuticals's estimated annual revenue is currently $15.5M per year.(i)
  • VenatoRx Pharmaceuticals received $42.0M in venture funding in July 2017.
  • VenatoRx Pharmaceuticals's estimated revenue per employee is $201,000
  • VenatoRx Pharmaceuticals's total funding is $107M.

Employee Data

  • VenatoRx Pharmaceuticals has 77 Employees.(i)
  • VenatoRx Pharmaceuticals grew their employee count by -4% last year.

VenatoRx Pharmaceuticals's People

NameTitleEmail/Phone
1
Chief Development Officer and VP Business DevelopmentReveal Email/Phone
2
SVP Medical SciencesReveal Email/Phone
3
VP Medical AffairsReveal Email/Phone
4
ControllerReveal Email/Phone
5
VP, MicrobiologyReveal Email/Phone
6
SVP, Commercial StrategyReveal Email/Phone
7
VP, Regulatory AffairsReveal Email/Phone
8
VP Clinical ScienceReveal Email/Phone
9
Head Human ResourcesReveal Email/Phone
10
VP, Non-Clinical SafetyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is VenatoRx Pharmaceuticals?

Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$107M

Total Funding

77

Number of Employees

$15.5M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

VenatoRx Pharmaceuticals News

2022-03-30 - Venatorx Pharmaceuticals Raises Series C Financing

Venatorx Pharmaceuticals, Inc., a Malvern, PA-based private, clinical-stage pharmaceutical company focused on improving health outcomes for...

2022-03-30 - AMR Action Fund Announces First Investments in Adaptive ...

"Adaptive Phage Therapeutics and Venatorx Pharmaceuticals are poised to change the treatment landscape for drug-resistant infections," said AMR...

2022-03-30 - Venatorx Pharmaceuticals Raises Series C Financing Led by ...

Venatorx is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant...

2019-09-07 - VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

MALVERN, Pa.--(BUSINESS WIRE)--. VenatoRx Pharmaceuticals today announced that Joseph C. Larsen, Ph.D. has joined the Company as ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M7738%N/A
#2
$22.7M79-1%N/A
#3
$16.5M8241%N/A
#4
$22.4M838%N/A
#5
$21.3M87-6%N/A

VenatoRx Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2017-07-26$42.0MBVersant VenturesArticle